Subcutaneous tocilizumab is the first biologic agent approved by the FDA treat patients with systemic sclerosis-associated interstitial lung disease.
Non-Invasive Vagus Nerve Stimulation Tolerated, Effective for Rheumatoid Arthritis
(Reuters Health)—Non-invasive vagus nerve stimulation is safe and effective as an intervention for rheumatoid arthritis (RA), a small proof-of-concept study suggests. The study enrolled 35 patients with active RA and an inadequate response to therapy with disease-modifying anti-rheumatic drugs (DMARDs). All DMARDS were discontinued four weeks prior to the trial. For the study, all participants…
Grit, Gratitude & Grace: Resilience Despite the Pain
Clinicians can help their patients tap into personal resilience, and such characteristics as grit, gratitude and grace, to manage their chronic pain, says Afton L. Hassett, PsyD.
FDA Approves Belimumab & Voclosporin for Lupus Nephritis
In December, the FDA approved belimumab, the first drug approved to treat lupus nephritis, an historic action that was rapidly followed in January by the approval of a second treatment for lupus nephritis, voclosporin.
ACR Endorses Woodcock for FDA Commissioner, Begins Relationship Building with New Administration Leaders
With the approval of its Board of Directors, the ACR sent a letter to President Biden and newly minted Secretary of Health & Human Services Xavier Becerra, strongly supporting Janet Woodcock, MD, to be nominated as the FDA’s permanent commissioner. The ACR also congratulated Secretary Becerra upon his confirmation.
When Switching Patients to Biosimilars, Communication & Expert Nurses Reduce the Nocebo Effect
In a recent study, researchers designed an intervention centered on communication and led by nurses to address discontinuation rates among patients who had switched to a biosimilar. The nurses’ insight and experience reduced the nocebo effect during the intervention, which had an 84% retention rate for patients taking a biosimilar after one year.
Louisa Ziglar, MD, FACR: ‘Everyone Can Be an Advocate’
When it comes to advocating for rheumatology, it’s never too early or late in your career to begin, and no effort is too small to have an impact, says Dr. Ziglar, a private practitioner and member of the Government Affairs Committee.
Improving Demographic Representation & Equity in Rheumatology Research
A better understanding of knowledge gaps and increased engagement of underrepresented communities are needed to diversify rheumatology patient data in clinical datasets, registries and randomized clinical trials.
COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
State-level wins that ensure immunosuppressed patients can access COVID-19 vaccination show the power of coordinated efforts by volunteer leaders, staff and members to translate the ACR’s work into actionable public policy recommendations, then amplify those messages through member engagement.
Pediatric Rheumatology Workforce Challenges in the Dakotas
Pediatric rheumatologists are few and far between in rural America. Financial incentives, such as loan repayment, may help draw more providers to the subspecialty and the underserved regions of the U.S.
- « Previous Page
- 1
- …
- 152
- 153
- 154
- 155
- 156
- …
- 814
- Next Page »